<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01909908</url>
  </required_header>
  <id_info>
    <org_study_id>12-014</org_study_id>
    <nct_id>NCT01909908</nct_id>
  </id_info>
  <brief_title>ECM and Blood Components for Wound Healing</brief_title>
  <official_title>Treatment of Chronic Wounds Using Extracellular Matrix-Based Devices and the Patient's Own Blood Components</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cook Group Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cook Group Incorporated</source>
  <brief_summary>
    <textblock>
      The Extracellular Matrix (ECM) and Blood Components for Wound Healing feasibility study is a
      clinical trial approved by Health Canada to study the safety of extracellular matrix (ECM)
      and autologous blood products in wound healing.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Slow enrollment
  </why_stopped>
  <start_date>February 2013</start_date>
  <completion_date type="Actual">September 2016</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Ulcer</condition>
  <condition>Venous Ulcer</condition>
  <condition>Foot Ulcer, Diabetic</condition>
  <arm_group>
    <arm_group_label>ECM in Saline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Blood Products</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ECM in Blood Products</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ECM</intervention_name>
    <description>ECM in saline applied to wound</description>
    <arm_group_label>ECM in Saline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Blood Products</intervention_name>
    <description>Autologous blood product applied to wound, with saline cleanse on alternating weeks</description>
    <arm_group_label>Blood Products</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ECM in Blood Products</intervention_name>
    <description>Alternating treatments of ECM in saline and ECM in autologous blood products, applied to wound</description>
    <arm_group_label>ECM in Blood Products</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 1 or Type 2 diabetes, and/or venous insufficiency to the affected leg

          -  Ulcer has been present between 12 and 52 weeks

          -  Ulcer is less than 40 cm2 in area

        Exclusion Criteria:

          -  Less than 18 years of age

          -  Pregnant or planning to become pregnant during the study period

          -  Simultaneously participating in another investigational drug or device study

          -  Unable or unwilling to comply with the weekly study follow-up schedule or off-loading
             regimen

          -  Patient or legal representative refuses to sign the EC-approved informed consent form

          -  Known allergy to pig or porcine products

          -  Additional criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Embil, MD, FRCPC</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Manitoba</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Health Sciences Centre</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3A 1R9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 25, 2013</study_first_submitted>
  <study_first_submitted_qc>July 26, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 29, 2013</study_first_posted>
  <last_update_submitted>September 28, 2016</last_update_submitted>
  <last_update_submitted_qc>September 28, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Wounds and injuries</keyword>
  <keyword>Ulcer</keyword>
  <keyword>Diabetic angiopathies</keyword>
  <keyword>Diabetic foot</keyword>
  <keyword>Venous insufficiency</keyword>
  <keyword>Extracellular matrix</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Foot Ulcer</mesh_term>
    <mesh_term>Varicose Ulcer</mesh_term>
    <mesh_term>Diabetic Foot</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

